We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Kazia Therapeutics Limited is a biotechnology business based in Australia. Kazia Therapeutics shares (KZA) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Kazia Therapeutics has a trailing 12-month revenue of around $363,489. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
| 52-week range | $0.5 - $1.88 |
|---|---|
| 50-day moving average | $1.3065 |
| 200-day moving average | $1.349 |
| Target price | $0.22 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.179 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$1.27
| 1 month (2021-07-02) | -3.79% |
|---|---|
| 3 months (2021-05-04) | -8.63% |
| 5 years (2016-07-31) | inf% |
|---|
| Revenue TTM | $363,489 |
|---|---|
| Gross profit TTM | $988,000 |
| Return on assets TTM | -26.94% |
| Return on equity TTM | -58.95% |
| Profit margin | 0% |
| Book value | 0.251 |
| Market capitalisation | $165.3 million |
TTM: trailing 12 months
We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.
Kazia Therapeutics 's shares were split on a 1:10 basis on 16 November 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics 's share price.
Over the last 12 months, Kazia Therapeutics 's shares have ranged in value from as little as $0.5 up to $1.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Kazia Therapeutics 's is 2.7003. This would suggest that Kazia Therapeutics 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. It has collaboration agreements with St Jude Children's Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and the University of Newcastle. Kazia Therapeutics Limited also has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug paxalisib in primary central nervous system lymphoma; Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083; and Joan & Sanford I Weill Medical College of Cornell University for Phase II clinical study using Paxalisib in combination with ketogenic diet for glioblastoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Everything we know about the X2M Connect IPO, plus information on how to buy in.
Steps to owning and managing Industrial Minerals shares.
Everything we know about the SSH Group IPO, plus information on how to buy in.
Everything we know about the Iris Metals IPO, plus information on how to buy in.
Everything we know about the Li-S Energy IPO, plus information on how to buy in.
Everything we know about the Clarity Pharmaceuticals IPO IPO, plus information on how to buy in.
Everything we know about the TEK-Ocean Group IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
